Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Award: Doctoral Foreign Study Award (DFSA)

Direct Payment

$105,000.00

VASPS (Vaping and Smoking Project in Schizophrenia): A controlled evaluation of abstinence-induced withdrawal among people with schizophrenia who vape versus smoke daily

EF 2023-24

Résumé
Health disparity is increasingly becoming a focus of psychologists in Canada and the United States. We aim to be at the forefront of understanding and ameliorating health disparities via rigorous scientific research. Smoking cessation in people with schizophrenia (SCZ) is a key need. Smoking prevalence has decreased dramatically in the general population, in part due to improvements in smoking cessation research. However, in people with SCZ it remains considerably high (88%), with low rates of cessation. Investigation of e-cigarettes (ENDS) as a smoking cessation tool in people with and without SCZ is burgeoning in recent years. Two major concerns with this direction of research are: a) that people with SCZ may be more vulnerable to ENDS dependency as a result of multiple disease-related factors and b) the addiction liability of ENDS in people with SCZ is unknown. Specifically, there is currently no research investigating indices of withdrawal from ENDS in people with SCZ. Withdrawal is a multi-faceted (e.g., craving, negative mood, cognitive impairment) component of tobacco/nicotine use disorder and is often the target of current and emerging cessation treatments. Before promoting ENDS as a treatment option, it is imperative to first understand vaping withdrawal and how it compares to smoking withdrawal among people with SCZ. The proposed study will a) assess effects of 24-hr abstinence from vaping vs smoking on self-report and objective assessments of major facets of withdrawal, as well as changes in neuropsychiatric symptoms (e.g. motivation, attention) and b) compare vaping/smoking withdrawal in people with SCZ to people without SCZ. The results of this study will inform key targets for vaping cessation treatment in SCZ and will be a major step towards increasing health equity in people with SCZ and substance use disorders, a historically underrepresented population
Programme
Doctoral Award: Doctoral Foreign Study Award (DFSA)
Bénéficiaire
Emplacement
New York, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
495288
Name
Johnstone Samantha
Region
New York
Country
United States of America
Orgtype
Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Clinical
Prcname2
Doctoral Research Awards - A
Projecttitle
VASPS (Vaping and Smoking Project in Schizophrenia): A controlled evaluation of abstinence-induced withdrawal among people with schizophrenia who vape versus smoke daily
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award: Doctoral Foreign Study Award (DFSA)
Keyworddelim
Cognitive Functioning; Cooccurring Disorders; Craving; Health Equity; Schizophrenia; Smoking; Vaping; Withdrawal
Abstract
Health disparity is increasingly becoming a focus of psychologists in Canada and the United States. We aim to be at the forefront of understanding and ameliorating health disparities via rigorous scientific research. Smoking cessation in people with schizophrenia (SCZ) is a key need. Smoking prevalence has decreased dramatically in the general population, in part due to improvements in smoking cessation research. However, in people with SCZ it remains considerably high (88%), with low rates of cessation. Investigation of e-cigarettes (ENDS) as a smoking cessation tool in people with and without SCZ is burgeoning in recent years. Two major concerns with this direction of research are: a) that people with SCZ may be more vulnerable to ENDS dependency as a result of multiple disease-related factors and b) the addiction liability of ENDS in people with SCZ is unknown. Specifically, there is currently no research investigating indices of withdrawal from ENDS in people with SCZ. Withdrawal is a multi-faceted (e.g., craving, negative mood, cognitive impairment) component of tobacco/nicotine use disorder and is often the target of current and emerging cessation treatments. Before promoting ENDS as a treatment option, it is imperative to first understand vaping withdrawal and how it compares to smoking withdrawal among people with SCZ. The proposed study will a) assess effects of 24-hr abstinence from vaping vs smoking on self-report and objective assessments of major facets of withdrawal, as well as changes in neuropsychiatric symptoms (e.g. motivation, attention) and b) compare vaping/smoking withdrawal in people with SCZ to people without SCZ. The results of this study will inform key targets for vaping cessation treatment in SCZ and will be a major step towards increasing health equity in people with SCZ and substance use disorders, a historically underrepresented population
Competitiondate
202310
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Johnstone, Samantha
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~